Abstract
As cell therapies begin to enter commercialization stages, bottlenecks and lack of appropriate manufacturing platforms for upstream and downstream cell processing limit production and potentially impact cell quality. Scalable, closed, automated platforms, with built-in process control are needed to allow commercialization of allogeneic cell therapy products.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
